TWD 51.5
(-2.83%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -653.8 Million TWD | -94.4% |
2022 | -336.31 Million TWD | -33.77% |
2021 | -251.41 Million TWD | 5.75% |
2020 | -266.75 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -813.31 Million TWD | -24.4% |
2024 Q2 | -798.42 Million TWD | 1.83% |
2023 Q3 | -1.41 Billion TWD | -234.62% |
2023 FY | -653.8 Million TWD | -94.4% |
2023 Q1 | -423.82 Million TWD | -26.02% |
2023 Q2 | -421.77 Million TWD | 0.48% |
2023 Q4 | -653.8 Million TWD | 53.68% |
2022 Q4 | -336.31 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | 467.074% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | 2147.879% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | 629.668% |
TTY Biopharm Company Limited | -705.97 Million TWD | 7.39% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 142.977% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 121.047% |
Center Laboratories, Inc. | 3.91 Billion TWD | 116.683% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | -1035.948% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 203.188% |
InnoPharmax Inc. | -17.85 Million TWD | -3561.138% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 29.454% |
Excelsior Biopharma Inc. | -212.51 Million TWD | -207.655% |
DV Biomed Co., Ltd. | 160.7 Million TWD | 506.849% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 16.331% |
UniPharma Co., Ltd. | -68.36 Million TWD | -856.318% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 232.778% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | 11.415% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | -240.861% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | -33514.704% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | -2300.874% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | -14.957% |